Stage IV sarcoidosis: Comparison of survival with the general population and causes of death

European Respiratory Journal

Volumn 38, Issue 6, 2011, Pages 1368-1373

  Nardi, A ^a   Brillet, P Y ^a   Letoumelin, P ^a   Girard, F ^a   Brauner, M ^a   Uzunhan, Y ^a   Naccache, J M ^a   Valeyre, D ^a   Nunes, H ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Mortality; Prognosis; Pulmonary hypertension; Sarcoidosis; Stage IV

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXYGEN; THALIDOMIDE;

ACUTE RESPIRATORY FAILURE; ADULT; ARTICLE; ASPERGILLOMA; CAUSE OF DEATH; CHRONIC RESPIRATORY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART SARCOIDOSIS; HEMOPTYSIS; HUMAN; LONG TERM CARE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NOCARDIOSIS; OXYGEN THERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SARCOIDOSIS; SURVIVAL RATE; TREATMENT RESPONSE; TUBERCULOSIS;

ADULT; ASPERGILLOSIS; CAUSE OF DEATH; FEMALE; FRANCE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; OXYGEN INHALATION THERAPY; PREVALENCE; PROGNOSIS; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 82555189240     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00187410     Document Type: Article

References (34)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-755.
2. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361: 1111-1118. (Pubitemid 36369566)
3. Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002; 121: 32-39. (Pubitemid 34114225)
4. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 52: 525-533. (Pubitemid 14245588)
5. Baughman RP, Winget DB, Bowen EH, et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14: 154-158. (Pubitemid 27427348)
6. Chappell AG, Cheung WY, Hutchings HA. Sarcoidosis: a longterm follow up study. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 167-173.
7. Hillerdal G, Nou E, Osterman K, et al. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis 1984; 130: 29-32. (Pubitemid 14092975)
8. James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann NY Acad Sci 1976; 278: 321-334.
9. Johnston RN. Pulmonary sarcoidosis after ten to twenty years. Scott Med J 1986; 31: 72-78. (Pubitemid 16060236)
10. Mayock RL, Bertrand P, Morrison CE, et al. Manifestations of sarcoidosis. analysis of 145 patients, with a review of nine series selected from the literature. Am J Med 1963; 35: 67-89.
11. Reich JM, Johnson RE. Course and prognosis of sarcoidosis in a nonreferral setting. Analysis of 86 patients observed for 10 years. Am J Med 1985; 78: 61-67. (Pubitemid 15159620)
12. Romer FK. Presentation of sarcoidosis and outcome of pulmonary changes. Dan Med Bull 1982; 29: 27-32. (Pubitemid 12149959)
13. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J 1961; 2: 1165-1172.
14. Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974; 57: 847-852.
15. Sones M, Israel HL. Course and prognosis of sarcoidosis. Am J Med 1960; 29: 84-93.
16. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889. (Pubitemid 33152325)
17. Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am J Med 1996; 100: 423-427. (Pubitemid 26115197)
18. Viskum K, Vestbo J. Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage. Eur Respir J 1993; 6: 349-353. (Pubitemid 23114879)
19. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-985. (Pubitemid 44787169)
20. Hwang JS, Wang JD. Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies. Stat Med 1999; 18: 1627-1640.
21. Ricci RP, Morichelli L, Gargaro A, et al. Home monitoring in patients with implantable cardiac devices: is there a potential reduction of stroke risk? Results from a computer model tested through Monte Carlo simulations. J Cardiovasc Electrophysiol 2009; 20: 1244-1251.
22. Doucet A, de Freitas N, Gordon NJ. In: Doucet A, de Freitas N, Gordon NJ, eds. Sequential Monte Carlo Methods in Practice. New York, Springer-Verlag, 2004; pp. 10-55.
23. Institut National de la Statistique et des Etudes Economiques. Table de mortalité 2006-2008. [Mortality tables 2006-2008]. www.ined.fr/fr/pop- chiffres/france/mortalite-causes-deces/table-mortalite Date last updated: July 5, 2011.
24. Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol 2000; 174: 1751-1757. (Pubitemid 30346752)
25. Freundlich IM, Libshitz HI, Glassman LM, et al. Sarcoidosis. Typical and atypical thoracic manifestations and complications. Clin Radiol 1970; 21: 376-383.
26. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999; 78: 65-111. (Pubitemid 29153026)
27. Wollschlager C, Khan F. Aspergillomas complicating sarcoidosis. A prospective study in 100 patients. Chest 1984; 86: 585-588. (Pubitemid 14011186)
28. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32: 296-302.
29. Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128: 1483-1489. (Pubitemid 41324436)
30. Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25: 783-788. (Pubitemid 40667674)
31. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124: 922-928. (Pubitemid 37123310)
32. Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120: 873-880. (Pubitemid 32885463)
33. Baughman RP, Shipley R, Desai D. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 2099; 136: 526-535.
34. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170: 1324-1330. (Pubitemid 39657197)